


## IBT6A

Cat. No.:	HY-13036A
CAS No.:	1022150-12-4
Molecular Formula:	C <sub>22</sub> H <sub>22</sub> N <sub>6</sub> O
Molecular Weight:	386.45
Target:	Btk
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    2 years -20°C    1 year



## SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (129.38 mM; ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		2.5877 mL	12.9383 mL	25.8766 mL
		5 mM		0.5175 mL	2.5877 mL	5.1753 mL
		10 mM		0.2588 mL	1.2938 mL	2.5877 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (6.47 mM); Suspended solution; Need ultrasonic					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution					

## BIOLOGICAL ACTIVITY

Description	IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct <sup>[1]</sup> . Ibrutinib is a selective, irreversible Btk inhibitor with an IC <sub>50</sub> of 0.5 nM <sup>[2]</sup> .
In Vitro	IBT6A (Compound 14) can be used in synthesis of Ibrutinib and Ibrutinib-based activity-based probes (ABPs) <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

- [1]. Liu N, et al. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. *Org Biomol Chem*. 2015 May 14;13(18):5147-57.
- [2]. Somana Siva Prasad, et al. A QUALITY BY DESIGN APPROACH FOR DEVELOPMENT OF SIMPLE AND ROBUST REVERSED PHASE STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF IBRUTINIB AND ITS IMPURITIES.
- [3]. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc Natl Acad Sci U S A*. 2010 Jul 20;107(29):13075-80.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA